These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 15134556)

  • 61. Glycoprotein IIb/IIIa receptor therapy in percutaneous coronary intervention and non-ST-segment elevation acute coronary syndromes. Estimating the economic implications.
    Hillegass WB; Newman AR; Raco DL
    Pharmacoeconomics; 2001 Jan; 19(1):41-55. PubMed ID: 11252545
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Glycoprotein IIb/IIIa inhibitors: an update on the mechanism of action and use of functional testing methods to assess antiplatelet efficacy.
    Lippi G; Montagnana M; Danese E; Favaloro EJ; Franchini M
    Biomark Med; 2011 Feb; 5(1):63-70. PubMed ID: 21319966
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials.
    Chew DP; Bhatt DL; Sapp S; Topol EJ
    Circulation; 2001 Jan; 103(2):201-6. PubMed ID: 11208677
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Current knowledge of the platelet glycoprotein IIb/IIIa receptor antagonists for the treatment of coronary artery disease.
    Berkowitz SD
    Haemostasis; 2000; 30 Suppl 3():27-43. PubMed ID: 11182626
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Efficacy and safety of glycoprotein IIb/IIIa receptor antagonists for patients undergoing percutaneous coronary intervention within twelve hours of fibrinolysis.
    Belle L; Fourny M; Reynaud T; Hammer L; Vanzetto G; Labarère J;
    Catheter Cardiovasc Interv; 2011 Sep; 78(3):376-84. PubMed ID: 21413113
    [TBL] [Abstract][Full Text] [Related]  

  • 66. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
    Adgey AA
    Eur Heart J; 1998 Apr; 19 Suppl D():D10-21. PubMed ID: 9597518
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Pharmacokinetics and pharmacodynamics of glycoprotein IIb-IIIa inhibitors.
    Kleiman NS
    Am Heart J; 1999 Oct; 138(4 Pt 2):263-75. PubMed ID: 10502232
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis.
    Montalescot G; Borentain M; Payot L; Collet JP; Thomas D
    JAMA; 2004 Jul; 292(3):362-6. PubMed ID: 15265852
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The role of platelet glycoprotein IIb/IIIa antagonists in percutaneous coronary revascularization procedures.
    Dangas G; Fuster V
    Rev Port Cardiol; 1999 Feb; 18 Suppl 1():I49-53. PubMed ID: 10191675
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Platelet glycoprotein IIb/IIIa inhibitors in coronary artery disease].
    Auer J; Berent R; Lassnig E; Weber T; Maurer E; Eber B
    Herz; 2003 Aug; 28(5):393-403. PubMed ID: 12928738
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy.
    Saw J; Lincoff AM; DeSmet W; Betriu A; Rutsch W; Wilcox RG; Kleiman NS; Wolski K; Topol EJ;
    J Am Coll Cardiol; 2004 Sep; 44(6):1194-9. PubMed ID: 15364319
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Oral platelet glycoprotein IIb/IIIa receptor inhibitors--part II.
    Cannon CP
    Clin Cardiol; 2003 Sep; 26(9):401-6. PubMed ID: 14524594
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Antiplatelet therapies: platelet GPIIb/IIIa antagonists and beyond.
    Mousa SA
    Curr Pharm Des; 2003; 9(28):2317-22. PubMed ID: 14529393
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Oral platelet glycoprotein IIb/IIIa receptor inhibitors--Part I.
    Cannon CP
    Clin Cardiol; 2003 Aug; 26(8):358-64. PubMed ID: 12918637
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Platelet glycoprotein IIb/IIIa polymorphism and coronary artery disease: implications for clinical practice.
    Di Castelnuovo A; de Gaetano G; Benedetta Donati M; Iacoviello L
    Am J Pharmacogenomics; 2005; 5(2):93-9. PubMed ID: 15813672
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Small-molecule glycoprotein IIb/IIIa inhibitors as adjunctive therapy in percutaneous coronary interventions.
    O'Shea JC; Tcheng JE
    J Thromb Thrombolysis; 2000 Dec; 10(3):211-5. PubMed ID: 11122539
    [No Abstract]   [Full Text] [Related]  

  • 77. Platelet glycoprotein IIb/IIIa antagonists in clinical trials for the treatment of coronary artery disease.
    Salam AM; Suwaidi JA
    Expert Opin Investig Drugs; 2002 Nov; 11(11):1645-58. PubMed ID: 12437510
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Synthesis and pharmacology of modified amidine isoxazoline glycoprotein IIb/IIIa receptor antagonists.
    Sielecki TM; Liu J; Mousa SA; Racanelli AL; Hausner EA; Wexler RR; Olson RE
    Bioorg Med Chem Lett; 2001 Aug; 11(16):2201-4. PubMed ID: 11514170
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Antiplatelet therapies: from aspirin to GPIIb/IIIa-receptor antagonists and beyond.
    Mousa SA
    Drug Discov Today; 1999 Dec; 4(12):552-561. PubMed ID: 10557137
    [TBL] [Abstract][Full Text] [Related]  

  • 80. New drugs: fenoldopam mesylate, glycoprotein IIb/IIIa antagonists, and K+ATP-channel agonists.
    Vijayakumar E
    Int Anesthesiol Clin; 2002; 40(1):35-60. PubMed ID: 11910249
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.